Reversal of early acute rejection with increased doses of tacrolimus in liver transplantation: a pilot study
Boillot, O.; Viale, J.P.; Gratadour, P.; Meeus, P.; Souraty, P.; Le Derf, Y.; Mechet, I.; Scoazec, J.Y.; Berger, F.; Paliard, P.
Transplantation 66(9): 1182-1185
1998
ISSN/ISBN: 0041-1337 PMID: 9825815 Document Number: 492159
Background. In this pilot study, we present the results of treatment of early (3 months after liver transplantation) acute rejection episodes by increasing only the tacrolimus doses. Methods. Ten patients who received tacrolimus as primary treatment experienced acute mild (one case), moderate (four cases), or severe (five cases) rejection episodes. Tacrolimus dosing was increased 1-2 mg every 1 or 2 days until hepatic enzymes started to improve. Steroid basic daily doses were kept unchanged. Results. With the daily dose of tacrolimus increased by a median 1.89-fold (range: 1.2-5), alanine aminotransferase, bilirubin, and gamma-glutamyltranspeptidase levels rapidly reached normal values within the first month. During a median follow-up time of 19.5 months (range: 14-24), none of the 10 patients died or lost their graft. Control liver biopsies were done 13.5 months (range: 7-19) after rejection episode in all patients, and none demonstrated evidence of rejection or sequela. Conclusion. This pilot study suggests that increasing tacrolimus dosage could be considered as treatment against early acute rejection episodes including the severe grade.